Introduction
TAK-931
MALIGNANCIES, SOLID TUMORS
Cell division cycle 7 (CDC7) is a highly conserved serine/threonine kinase that has an essential role in initiation of DNA replication during replication stress [TAK-931 is a highly potent and selective CDC7 kinase inhibitor which is currently undergoing clinical evaluation for the treatment of various malignancies [An oral, powder-in-capsule (PIC) formulation of TAK-931, evaluated in a first-in-human phase 1 study in patients with solid tumors (NCT02699749), demonstrated an acceptable safety profile and preliminary antitumor activity [